camptothecin has been researched along with Squamous Cell Carcinoma of Head and Neck in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, B; Deng, H; Gu, S; Li, Y; Lin, C; Shen, Z; Wei, Z | 1 |
| Nanbu, K; Nanbu, T; Ohkoshi, E; Sakagami, H; Shimada, J; Umemura, N | 1 |
| Cooper, RC; Gui, Q; He, H; Wang, J; Yang, H | 1 |
| Chang, PM; Chen, SC; Yang, MH | 1 |
| Dahlstrom, KR; Gao, F; Han, P; Li, G; Liu, H; Liu, Z; Owzar, K; Sturgis, EM; Wei, Q; Zevallos, JP | 1 |
| Argiris, A; Arun, P; Feldman, LE; Forastiere, AA; Gilbert, J; Haigentz, M; Jang, M; Lee, JW; Van Waes, C | 1 |
2 trial(s) available for camptothecin and Squamous Cell Carcinoma of Head and Neck
| Article | Year |
|---|---|
Cisplatin/Tegafur/Uracil/Irinotecan Triple Combination Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: A Phase I/II Clinical Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Female; Head and Neck Neoplasms; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Squamous Cell Carcinoma of Head and Neck; Tegafur; Uracil | 2016 |
Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Camptothecin; Carcinoma, Squamous Cell; Cytokines; Disease Progression; Female; Head and Neck Neoplasms; Humans; Irinotecan; Male; Middle Aged; NF-kappa B; Pyrazines; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2013 |
4 other study(ies) available for camptothecin and Squamous Cell Carcinoma of Head and Neck
| Article | Year |
|---|---|
Neddylation inhibitor MLN4924 sensitizes head and neck squamous carcinoma cells to (S)-10-hydroxycamptothecin.
Topics: Camptothecin; Head and Neck Neoplasms; Humans; Squamous Cell Carcinoma of Head and Neck | 2023 |
Combined SN-38 and gefitinib treatment promotes CD44 degradation in head and neck squamous cell carcinoma cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Gefitinib; Head and Neck Neoplasms; Humans; Hyaluronan Receptors; Irinotecan; Lysosomes; Mice; Proteolysis; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Xenograft Model Antitumor Assays | 2018 |
Drug-Conjugated Dendrimer Hydrogel Enables Sustained Drug Release via a Self-Cleaving Mechanism.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Survival; Delayed-Action Preparations; Dendrimers; Drug Liberation; Head and Neck Neoplasms; Humans; Hydrogels; Injections; Male; Mice; Mice, Nude; Polyethylene Glycols; Squamous Cell Carcinoma of Head and Neck; Tumor Burden; Xenograft Model Antitumor Assays | 2019 |
Apoptotic capacity and risk of squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Alcohol Drinking; Apoptosis; Camptothecin; Carcinoma, Squamous Cell; Case-Control Studies; Female; Flow Cytometry; Head and Neck Neoplasms; Humans; Lymphocytes; Male; Middle Aged; Odds Ratio; Polymorphism, Genetic; Risk Factors; Smoking; Squamous Cell Carcinoma of Head and Neck; Topoisomerase I Inhibitors | 2017 |